round button
Leave a message

北美肺移植治疗市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

北美肺移植治疗市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • North America
  • 350 页面
  • 桌子數: 61
  • 图号: 43

北美肺移植治疗市场,按产品(免疫抑制药物、器官保存产品、组织产品等)、适应症(慢性阻塞性肺病、肺纤维化、脓性肺病、肺动脉高压、囊性纤维化、间质性肺纤维化、肺气肿、结节病、原发性肺动脉高压等)、类型(尸体肺移植、活体肺移植)、技术(单肺移植、双肺移植、心肺移植、双肺移植)、患者人口统计(老年人、成人、儿童)、最终用户(医院、移植中心、专科中心等)、国家(美国、加拿大和墨西哥)划分的行业趋势和预测(至 2029 年)

北美肺移植治疗市场

市场分析与洞察:北美肺移植治疗市场

北美肺移植治疗市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,该市场以 5.9% 的复合年增长率增长,预计到 2029 年将达到 1.1214 亿美元。由于污染增加导致手术和疗法的新创新治疗方法的增加以及呼吸道慢性疾病的增加是推动预测期内市场需求的主要驱动力。

用健康肺(通常来自已故捐赠者)替换患病或衰竭肺的外科手术。肺移植适用于尝试过其他药物或治疗但潜在疾病没有得到充分改善或随着时间的推移而恶化的患者。根据患者的医疗状况,肺移植可能涉及更换一个或两个肺。在某些情况下,肺可能与捐赠的心脏一起移植。肺移植可以显著改善患者的健康和生活质量。

肺部不健康或受损会使患者的身体难以获得维持日常身体功能所需的氧气。各种疾病和状况都会损害您的肺部并妨碍其有效运作。

推动肺移植治疗市场增长的主要因素是肺部相关疾病,例如慢性阻塞性肺病(COPD),包括肺气肿、肺部瘢痕(肺纤维化)、肺部高血压(肺动脉高压)和囊性纤维化疾病,以及一些正在进行的旨在增加治疗应用的研究,而阻碍肺移植治疗市场增长的因素是肺移植治疗和程序的高成本以及产品召回。

The lung transplant therapeutics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief; our team will help you create a revenue impact solution to achieve your desired goal.

北美肺移植治疗市场

North America Lung Transplant Therapeutics Market Scope and Market Size

North America lung transplant therapeutics market is segmented into product, type, indication, technique, patient demographics, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the North America global lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. In 2022, the immunosuppressant drugs segment is expected to dominate the global lung transplant therapeutics market due to the increase in the market due to increased organ donation and its applications.
  • On the basis of type, the North America global lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the global lung transplant therapeutics effectiveness of immune system suppressant drugs in patients to avoid lung rejection.
  • On the basis of indication, the North America global lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the global lung transplant therapeutics market due to the increase in the vulnerable older patient population of cystic fibrosis patients in region.
  • On the basis of technique, the North America global lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the global lung transplant therapeutics market due to the surge in case of smoking and other harmful tobacco products
  • 根据患者人口统计数据,北美全球肺移植治疗市场分为成人、儿童和老年。由于全球人口的增长,预计到 2022 年,成人市场将主导全球肺移植治疗市场。
  • 根据最终用户,北美全球肺移植治疗市场分为医院、移植中心、专科中心和其他。到 2022 年,由于拥有高效手术和高技能医生的医院数量增加,预计医院部门将主导全球肺移植治疗市场。

北美肺移植治疗市场

北美肺移植治疗市场国家级分析

对肺移植治疗市场进行分析,并根据产品、类型、适应症、技术、患者人口统计和最终用户提供市场规模信息。

北美肺移植治疗市场报告涵盖的国家包括美国、加拿大和墨西哥。

  • 2022 年,由于慢性阻塞性肺病 (COPD) 等肺部相关疾病的增加,预计美国将主导北美肺移植治疗市场。

由于预防慢性病的临床试验和研究开发不断增加,预计美国免疫抑制药物市场将在 2022 年至 2029 年的预测期内以最高增长率增长。加拿大预计也将实现增长,因为每年肺移植手术的增加导致移植药物的批准增加,研发投资不断增加,从而推动了制药创新。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。

严重肺部疾病患病率上升推动市场增长

北美肺移植治疗市场还为您提供详细的市场分析,包括每个国家肺移植行业的增长情况、销售额、肺移植技术进步的影响以及监管环境的变化及其对肺移植治疗市场的支持。数据涵盖 2012 年至 2020 年的历史时期。

竞争格局和肺移植治疗市场份额分析

肺移植治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上数据点仅与公司对北美肺移植治疗的关注有关。

北美肺移植治疗市场的一些主要制造商包括安斯泰来制药公司、诺华公司、辉瑞公司、罗氏公司、诺华公司、Accord UK Ltd、Panacea Biotech Ltd、Dr、Franz Kohler Chemie GMBH、Dr. Reddy's laboratories Ltd、Detraxi Inc、Hikma Pharmaceuticals PLC、Apotex Inc.、Intas Pharmaceuticals Ltd.、Viatris Inc.、Bridge to Life Ltd.、Transmedics Inc.、Paragonix Technologies Inc.、Xvivo、OSE Immunotherapeutics、BioLife Solutions 和 21st Century Medicine 等。

各种市场参与者提供更好的医疗服务,这也加速了肺移植治疗市场的发展

例如,

  • 2021 年 7 月,美国食品药品监督管理局根据一项提供真实世界有效性证据 (RWE) 的非干预性(观察性)研究批准了 Prograf(他克莫司)的新用途。FDA 批准 Prograf 与其他免疫抑制剂药物联合使用,以防止接受肺移植的成人和儿科患者的器官排斥

合作、产品发布、业务扩展、奖励和认可、合资企业和其他市场参与者增强了公司在肺移植治疗市场的地位,这也有利于该组织改善其产品供应。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USERS COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL ANALYSIS

4.3 PORTER’S FIVE FORCES MODEL

5 INSURANCE AND REIMBURSEMENT - NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET

5.1 U.S.

5.2 CANADA

6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS

6.1 REGULATION IN THE U.S.

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING

7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES

7.1.4 RISE IN CLINICAL TRIALS

7.1.5 INCREASING DRUG APPROVALS

7.2 RESTRAINTS

7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION

7.2.2 HIGH COST OF ORGAN TRANSPLANTATION

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE SPENDING

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY FRAMEWORK

7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION

8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES

8.5 CONCLUSION

9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 IMMUNOSUPPRESSANT DRUGS

9.2.1 BY CLASS

9.2.1.1 CALCINEURIN INHIBITORS

9.2.1.1.1 TACROLIMUS

9.2.1.1.2 CYCLOSPORIN

9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS

9.2.1.2.1 MYCOPHENOLATE MOFETIL

9.2.1.2.2 MYCOPHENOLATE SODIUM

9.2.1.2.3 AZATHIOPRINE

9.2.1.3 M-TOR INHIBITOR

9.2.1.3.1 SIROLIMUS

9.2.1.3.2 EVEROLIMUS

9.2.1.4 STEROIDS

9.2.1.4.1 METHYLPREDNISOLONE

9.2.1.4.2 PREDNISONE

9.2.1.5 MONOCLONAL ANTIBODY

9.2.1.5.1 BASILIXIMAB

9.2.1.5.2 MUROMONAB

9.2.1.6 OTHERS

9.2.2 BY DRUG TYPE

9.2.2.1 BRANDED

9.2.2.2 GENERIC

9.2.3 ROUTE OF ADMINISTRATION

9.2.3.1 ORAL ADMINISTRATION

9.2.3.2 PARENTERAL ADMINISTRATION

9.3 ORGAN PRESERVATION PRODUCTS

9.3.1 PERFADEX

9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION

9.3.3 LIFOR

9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION

9.3.5 RENOGRAF

9.3.6 OTHERS

9.4 TISSUE PRODUCT

9.5 OTHERS

10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE

10.1 OVERVIEW

10.2 SINGLE-LUNG TRANSPLANT (SLT)

10.3 DOUBLE LUNG TRANSPLANT

10.4 BILATERAL LUNG TRANSPLANT (BLT)

10.5 HEART-LUNG TRANSPLANT

11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS

11.1 OVERVIEW

11.2 ADULTS

11.3 GERIATRIC

11.4 PEDIATRIC

12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE

12.1 OVERVIEW

12.2 CADAVERIC LUNG TRANSPLANT

12.3 LIVING LUNG TRANSPLANT

13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION

13.1 OVERVIEW

13.2 CYSTIC FIBROSIS

13.3 PULMONARY FIBROSIS

13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

13.5 INTERSTITIAL PULMONARY FIBROSIS

13.6 PULMONARY HYPERTENSION

13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION

13.8 EMPHYSEMA

13.9 SARCOIDOSIS

13.1 SEPTIC LUNG DISEASE

13.11 OTHERS

14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITAL

14.3 TRANSPLANT CENTERS

14.4 SPECIALTY CENTERS

14.5 OTHERS

15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY

15.1 OVERVIEW

15.1.1 U.S.

15.1.2 CANADA

15.1.3 MEXICO

16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 ASTELLAS PHARMA INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENT

18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 DR. REDDY’S LABORATORIES LTD.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 F.HOFFMANN-LA ROCHE LTD.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 HIKMA PHARMACEUTICALS PLC

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 APOTEX INC

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 XVIVO

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 ACCORD-UK LTD

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 BIOLIFE SOLUTIONS

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 BRIDGE TO LIFE LTD

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 DETRAXI, INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 INTAS PHARMACEUTICALS LTD.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 NOVARTIS AG

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 PANACEA BIOTEC LTD.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 PARAGONIX TECHNOLOGIES, INC

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENTS

18.15.3.1 PRODUCT LAUNCH

18.15.3.2 PARTNERSHIP

18.16 PFIZER INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENT

18.17 VIATRIS, INC

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 21ST CENTURY MEDICINE

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

TABLE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 17 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 18 U.S. IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 19 U.S. CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 20 U.S. ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 21 U.S. M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 22 U.S. STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 23 U.S. MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 24 U.S. IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 25 U.S. IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 U.S. ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 27 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 28 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 30 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 31 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 33 CANADA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 34 CANADA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 35 CANADA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 36 CANADA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 37 CANADA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 38 CANADA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 39 CANADA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 40 CANADA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 41 CANADA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 42 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 43 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 45 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 46 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 47 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 48 MEXICO IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 49 MEXICO CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 50 MEXICO ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 51 MEXICO M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 52 MEXICO STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 53 MEXICO MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 54 MEXICO IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 55 MEXICO IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 MEXICO ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 57 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 58 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 60 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 61 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION

FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET

FIGURE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021

FIGURE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 18 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021

FIGURE 19 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021

FIGURE 23 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 26 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021

FIGURE 27 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021

FIGURE 31 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE

FIGURE 34 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021

FIGURE 35 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)

FIGURE 39 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)

FIGURE 40 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)

FIGURE 43 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The North America Lung Transplant Therapeutics Market size will be worth USD 112.14 million by 2029.
The North America Lung Transplant Therapeutics Market growth rate will be 5.9% by 2029.
The Increase in new innovative treatment for surgeries and therapies and rise in respiratory chronic diseases due to rise in pollution are the growth drivers of the North America Lung Transplant Therapeutics Market.
The product, type, indication, technique, patient demographics, and end users are the factors on which the North America Lung Transplant Therapeutics Market research is based.
The major companies in the North America Lung Transplant Therapeutics Market are Astellas Pharma Inc, Novartis AG, Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Panacea Biotech Ltd, Dr, Franz Kohler Chemie GMBH, Dr. Reddy’s laboratories Ltd, Detraxi Inc, Hikma Pharmaceuticals PLC, Apotex Inc., Intas Pharmaceuticals Ltd., Viatris Inc., Bridge to Life Ltd., Transmedics Inc., Paragonix Technologies Inc., Xvivo, OSE Immunotherapeutics, BioLife Solutions, and 21st Century Medicine.
a